Neil Atkey

A Global Ring Study: Concordance Between Ventana PATHWAY Anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-Low Breast Cancer

Hans‐Ulrich Schildhaus, Sunil Badve, Corrado D’Arrigo, Gelareh Farshid et autres

Trastuzumab deruxtecan showed improved efficacy compared with the treatment of the physician's choice in human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer (BC) patients in the DESTINY-Breast04 and -06 phase 3 clinical …

us, au, de, es, fr, cn, Afrique du Sud, pl, it (code pays fourni par la source)

Abstract P1-03-28: Agreement between the DESTINY-Breast04/06 VENTANA 4B5 HER2 IHC clinical trial assay and other comparator assays for HER2-low breast cancer: Overall results of a large-scale, multicenter global ring study

Sunil Badve, Corrado D’Arrigo, Gelareh Farshid, Annette Lebeau et autres

Abstract Background: Treatment with trastuzumab deruxtecan improved outcomes compared with standard of care for human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+ with in situ hybridization negative) metastatic breast cancer (BC) in DESTINY-Breast04 and DESTINY-Breast06. The VENTANA …

Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer

Josef Rüschoff, Alexander Penner, Ian O. Ellis, M. Elizabeth Hammond et autres

CONTEXT.—: Recently, a new type of antibody-drug conjugate, trastuzumab-deruxtecan (T-DXd), has been approved for the treatment of metastatic breast cancer with low level of human epidermal growth factor receptor 2 (HER2) gene expression. Thereby, eligibility relies on an accurate diagnosis of HER2-low …

gb, us, de, jp, fr, es, it (code pays fourni par la source)

Abstract 1030: Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study

Hans‐Ulrich Schildhaus, Sunil Badve, Corrado D’Arrigo, Gelareh Farshid et autres

Abstract Background: DESTINY-Breast04 (DB-04) showed that trastuzumab deruxtecan improves survival vs chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+ with in situ hybridization negative) metastatic breast cancer (BC). The VENTANA 4B5(CDx) IHC assay, …

us, au, de, es, fr, cn, it (code pays fourni par la source)

Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer

Bharat Jasani, Philippe Tanière, Hans‐Ulrich Schildhaus, Kevin Blighe et autres

Claudin 18.2 (CLDN18.2), the dominant isoform of CLDN18 in gastric tissues, is a highly specific tight junction protein of the gastric mucosa with variably retained expressions in gastric and gastroesophageal junction cancers. Additionally, CLDN18.2-targeted treatment with zolbetuximab, in combination with chemotherapy, has …

gb (code pays fourni par la source)

Abstract HER2-13: HER2-13 Proficiency assessment of HER2-low breast cancer scoring with the Ventana PATHWAY 4B5 and Dako HercepTest HER2 assays and the impact of pathologist training

Josef Rüschoff, Alexander Penner, Ian O. Ellis, M. Elizabeth H. Hammond et autres

Abstract Background: Based on the results of the DESTINY-Breast04 study, the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) and the Ventana PATHWAY 4B5 companion diagnostic were recently approved by the US Food and Drug Administrated for the treatment and identification of patients with …

gb, us, de, jp, fr, es, it (code pays fourni par la source)

54P Assessment of EU4 laboratory readiness for FGFR2 fusion testing of cholangiocarcinoma by NGS

Marianna Sciortino, Neil Atkey, Brigitte Bisarò, Gilles Courtois et autres

Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands

Syed Ali Khurram, Jemel Sultan-Khan, Neil Atkey, Paul Michael Speight

gb (code pays fourni par la source)

International comparison of BRAF testing in melanoma.

Marcos Tadeu dos Santos, Neil Atkey, Eloise Aita, Jordan J. Clark

e21053 Background: According to current NCCN guidelines, melanoma patients with metastatic or unresectable disease should be tested for BRAF V600 mutations to evaluate therapy options. Test adoption was analyzed by comparing BRAF testing volumes for eligible melanoma patients in six countries. Methods: …

Targeting EGFR and PI3K pathways in ovarian cancer

Sharon Glaysher, Louise M Bolton, Peter Johnson, Neil Atkey et autres

BACKGROUND: The epidermal growth factor receptor (EGFR) is expressed in ovarian cancer, but agents targeting this pathway have shown little effect as single agents. This may be due to the presence of alternative pathways, particularly activation of the PI3K/Akt/MTOR pathway. METHODS: We …

gb (code pays fourni par la source)

Fluorescence in situ hybridisation (FISH) in histologically challenging conjunctival melanocytic lesions

Hardeep Singh Mudhar, Kath Smith, Polly Talley, Abigail Whitworth et autres

BACKGROUND: Even in experienced hands, the classification of some melanocytic lesions of the conjunctiva remains challenging. In skin pathology, the recent application of fluorescence in situ hybridisation (FISH) has been demonstrated to be of use for the analysis and diagnosis of ambiguous …

gb (code pays fourni par la source)

P2.15 Targeting Egfr and PI3K Pathways in Ovarian Cancer

Angela Jane Cree, Michael Alan Glaysher, Louise M Bolton, Peter Johnson et autres

gb (code pays fourni par la source)